Omega-3 Fatty Acids and Longevity: EPA, DHA, and What the Research Shows

ThrivStack Research Team July 1, 2026 4 min read

Omega-3 Fatty Acids and Longevity: EPA, DHA, and What the Research Shows

Few supplements have as much clinical trial data behind them as omega-3 fatty acids. The evidence base spans cardiovascular disease, cognitive aging, inflammation, and now — through the lens of hallmarks of aging research — mechanisms relevant to longevity itself.

EPA and DHA: What They Are and Why They Matter

The omega-3 fatty acids with the strongest evidence for human health are EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Both are long-chain polyunsaturated fatty acids found primarily in fatty fish and marine algae.

EPA is the primary precursor to anti-inflammatory eicosanoids — signaling molecules that modulate immune function and resolve inflammation. DHA is a structural component of cell membranes throughout the body, particularly in the brain (where it makes up approximately 15-20% of total fatty acid content in the cerebral cortex) and in the retina.

ALA (alpha-linolenic acid), found in flaxseed and walnuts, is a plant-based omega-3 but converts to EPA and DHA very inefficiently (under 5% in most adults), making it an inadequate substitute for direct EPA/DHA supplementation.

Cardiovascular Evidence: Where Omega-3s Stand

The cardiovascular story for omega-3s has had several plot twists. Early meta-analyses showing significant reductions in cardiovascular events were followed by trials with null results, leading to controversy in the 2010s.

The picture clarified substantially with REDUCE-IT (2018) and STRENGTH (2020). REDUCE-IT, using 4g/day of purified EPA (icosapentaenoic acid) in patients with elevated triglycerides and established cardiovascular disease or diabetes, reduced major cardiovascular events by 25% compared to placebo — a substantial and clinically meaningful result [1]. STRENGTH, using a different formulation (EPA + DHA), showed no significant benefit.

The divergence between these trials suggests that EPA specifically, rather than the EPA+DHA combination, may drive cardiovascular protection — and that dose matters significantly (most people take 1g/day, well below REDUCE-IT's 4g therapeutic dose).

Telomere Length and Cellular Aging

One of the most intriguing findings in omega-3 research is the association with telomere length. Telomeres are protective caps on chromosomes that shorten with each cell division; shorter telomeres are associated with accelerated biological aging and increased disease risk.

A randomized trial published in Brain, Behavior, and Immunity found that 4 months of omega-3 supplementation (2.5g/day) increased telomere length in healthy middle-aged and older adults by 4.3% compared to placebo — a meaningful difference given that telomere length changes slowly [2]. A second randomized trial confirmed the association, finding that omega-3 supplementation attenuated telomere shortening over time [3].

Brain Aging and Cognitive Decline

DHA is disproportionately concentrated in the brain, and its dietary intake is inversely associated with cognitive decline in observational studies. Higher blood DHA levels are associated with larger brain volume and reduced rates of cognitive decline in older adults.

A randomized trial in older adults with mild cognitive impairment found that 900mg/day of DHA over 24 weeks improved episodic memory and learning scores compared to placebo, with effects correlating with increases in blood DHA levels [4].

Inflammation: The Mechanistic Core

Chronic low-grade inflammation — sometimes called "inflammaging" — is now recognized as a driver of multiple age-related conditions including cardiovascular disease, neurodegeneration, cancer, and metabolic dysfunction. EPA and DHA reduce the production of pro-inflammatory eicosanoids (prostaglandin E2, leukotriene B4) and are precursors to specialized pro-resolving mediators (SPMs) — lipid compounds that actively resolve inflammation rather than simply suppressing it.

Synergies With Vitamin D and Astaxanthin

Vitamin D3 and omega-3s work synergistically on inflammation and immune function, and both are commonly deficient in the same populations. The VITAL trial found that combined vitamin D and omega-3 supplementation reduced cancer mortality more than either alone, suggesting additive effects [5].

Astaxanthin, a marine carotenoid with potent antioxidant properties, protects EPA and DHA from oxidative degradation — relevant because omega-3s are highly susceptible to peroxidation both in the supplement bottle and in the body.

Dosing and Quality

Clinical evidence supports 1-4g/day of combined EPA+DHA. For general longevity and anti-inflammatory purposes, 1-2g/day is a reasonable target. Triglyceride reduction and cardiovascular benefit at the level seen in REDUCE-IT require 4g/day.

Quality matters enormously with fish oil. Look for:

Disclaimer: This article is for informational purposes only. People on blood thinners should consult a physician before taking high-dose omega-3s.

References

[1] Bhatt DL et al. Cardiovascular risk reduction with icosapentaenoic acid for hypertriglyceridemia. New England Journal of Medicine. 2019;380:11-22.

[2] Kiecolt-Glaser JK et al. Omega-3 supplementation lowers inflammation and anxiety in medical students. Brain, Behavior, and Immunity. 2011;25(8):1725-1734.

[3] Farzaneh-Far R et al. Association of marine omega-3 fatty acid levels with telomeric aging in patients with coronary heart disease. JAMA. 2010;303(3):250-257.

[4] Yurko-Mauro K et al. Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline. Alzheimer's & Dementia. 2010;6(6):456-464.

[5] Manson JE et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. New England Journal of Medicine. 2019;380:23-32.